2848-96-6

Basic information

• Product Name: 3-(Acetyloxy)-7-chloro-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one
• Synonyms: 3-(ACETYLOXY)-7-CHLORO-5-(2-CHLOROPHENYL)-1,3-DIHYDRO-2H-1,4-BENZODIAZEPIN-2-ONE;7-chloro-5-(2-chlorophenyl)-1,3-dihydro-2-oxo-2H-1,4-benzodiazepin-3-yl acetate;lorazepam acetate;Acetic acid [7-chloro-5-(2-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin]-3-yl ester;Lorazepam 3-acetate;[7-chloro-5-(2-chlorophenyl)-2-oxo-1,3-dihydro-1,4-benzodiazepin-3-yl] acetate;[7-chloro-5-(2-chlorophenyl)-2-oxo-1,3-dihydro-1,4-benzodiazepin-3-yl] ethanoate;acetic acid [7-chloro-5-(2-chlorophenyl)-2-keto-1,3-dihydro-1,4-benzodiazepin-3-yl] ester
• CAS NO: 2848-96-6
• Molecular Formula: C₁₇H₁₂Cl₂N₂O₃
• Molecular Weight: 363.19
• EINECS: 220-653-7
• Mol File: 2848-96-6.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 524.4 °C at 760 mmHg
• Flash Point: 270.9 °C
• Appearance: /
• Density: 1.45 g/cm³
• Vapor Pressure: 4.33E-11mmHg at 25°C
• Refractive Index: 1.656
• BRN: 764089
• CAS DataBase Reference: 3-(Acetyloxy)-7-chloro-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(Acetyloxy)-7-chloro-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one(2848-96-6)
• EPA Substance Registry System: 3-(Acetyloxy)-7-chloro-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one(2848-96-6)

Safety Data

• Hazard Codes: Xn,N
• Statements: 22-50/53
• Safety Statements: 60-61
• RIDADR: UN 3077 9 / PGIII
• Hazardous Substances Data: 2848-96-6(Hazardous Substances Data)

Usage

General Description

"3-(Acetyloxy)-7-chloro-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one" refers to a chemical compound with a complex structure largely centered around a 1,4-benzodiazepine group, a common feature in many pharmaceutical compounds. The additional presence of multiple chlorinated and carbonylated phenyl groups--indicated by the "7-chloro", "2-chlorophenyl", and "acetyloxy" parts of the name--suggests that this chemical may be a derivative of a more basic benzodiazepine, likely one with distinctive properties. This chemical compound, like other benzodiazepines, may have potential applications in medical or pharmaceutical contexts, although it would be necessary to know more about its specific properties and effects to predict its usefulness in those areas.

InChI:InChI=1/C17H12Cl2N2O3/c1-9(22)24-17-16(23)20-14-7-6-10(18)8-12(14)15(21-17)11-4-2-3-5-13(11)19/h2-8,17H,1H3,(H,20,23)

Upstream product

• 127-08-2 potassium acetate 
• 2894-67-9 delorazepam 
• 2958-36-3 (2-amino-5-chloro-phenyl)-(2-chloro-phenyl)-methanone 
• 14405-03-9 2-chloroacetamido-2’,5-dichlorobenzophenone 
• 64-19-7 acetic acid 

Downstream Products

• 846-49-1 lorazepam 
• 71107-65-8 lorazepam-β-phenyl-propionate 
• 82841-78-9 lorazepam-α-chloro-propionate 
• 71107-66-9 lorazepam-α-methyl-β-phenyl-propionate 

Relevant articles and documents

Light-stabilized pharmaceutical composition, and preparation method and pharmaceutical application thereof

The invention relates to a light-stabilized pharmaceutical composition, and a preparation method and pharmaceutical application thereof. Specifically, the pharmaceutical composition comprises a lorazepam crystal and pharmaceutical adjuvants. The lorazepam crystal is radiated by Cu-K alpha. In a powder X-ray diffraction pattern expressed by an angle of 2 theta, there are diffraction peaks at approximately 12.17 degrees, approximately 14.15 degrees, approximately 15.27 degrees, approximately 16.84 degrees, approximately 17.91 degrees and approximately 20.81 degrees. For example, the crystal hasdiffraction peaks at approximately 7.93 degrees, approximately 9.04 degrees, approximately 12.17 degrees, approximately 14.15 degrees, approximately 15.27 degrees, approximately 16.84 degrees, approximately 17.91 degrees, approximately 20.81 degrees, approximately 21.44 degrees and approximately 26.38 degrees. A new crystal form and the pharmaceutical composition, which are used for preparing lorazepam and prepared by the method, exhibit excellent properties as described in the description of the invention.

New crystal form of lorazepam, preparation method and pharmaceutical applications thereof

The invention relates to a new crystal form for preparing lorazepam, a preparation method and pharmaceutical applications thereof, wherein specifically the lorazepam crystal has diffraction peaks at about 12.17 DEG, about 14.15 DEG, about 15.27 DEG, about 16.84 DEG, about 17.91 DEG and about 20.81 DEG in a powder X-ray diffraction pattern represented by a 2[theta] angle by using Cu-Kalpha radiation, for example, the crystal has diffraction peaks at about 7.93 DEG, about 9.04 DEG, about 12.17 DEG, about 14.15 DEG, about 15.27 DEG, about 16.84 DEG, about 17.91 DEG, about 20.81 DEG, about 21.44 DEG and about 26.38 DEG. The invention further provides a preparation method of the new crystal of larazepam, and pharmaceutical applications of the new crystal form. According to the invention, the prepared new crystal form for preparing lorazepam shows excellent properties defined in the specification.

Efficient synthesis of 3-hydroxy-1,4-benzodiazepines oxazepam and lorazepam by new acetoxylation reaction of 3-position of 1,4-benzodiazepine ring

Simple, efficient, and scalable syntheses of 3-hydroxy-1,4-benzodiazepines, oxazepam (1), and lorazepam (2) were developed. The syntheses are based on the new acetoxylation reaction of the 3-position of the 1,4-benzodiazepine ring. The reaction involves iodine (20-50 mol %)-catalyzed acetoxylation in the presence of potassium acetate (2 equiv) and potassium peroxydisulfate (1-2 equiv) as a stoichiontetric oxidant affording the corresponding 3-acetoxy-1,4- benzodiazepines in good-to-high yields. The latter were converted by selective saponification to 3-hydroxy-1,4-benzodiazepines of very high purity (>99.8%) in an overall yield of 83% (oxazepam) and 64% (lorazepam).